Der Nutzen überwiegt - Rosiglitazon hat weiter grünes Licht von EMEA und FDA

Literatur

• 01 Nissen SE . Wolski K . Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.  N Engl J Med. 2007;  356 2457-2471
• 02 Singh S . Loke YK . Furberg CD . Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.  JAMA. 2007;  298 (10) 1189-1195
• 03 Lincoff AM . et al . Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.  JAMA. 2007;  298 (10) 1180-1188
• 04 Lago RM . Singh PP . Nesto RW . Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-anlaysis of randomised clinical trials.  Lancet. 2007;  370 1129-1136
• 05 Home PD . Pocock SJ . Beck-Nielsen H . et al . Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007; 357: 10.1056/NEJMoa073394. 
• 06 Nussbaum SR . Risk for Myocardial Infarction in Patients Treated with Thiazolidinediones. Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. Available at: http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4308s1-00-index.htm. Accessed Aug. 17, 2007. 
• 07 Kahn SE . et al . Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy.  N Engl J Med. 2006;  355 2427-2443